Related Experiment Video
Updated: Jun 22, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Insulin analogs and pregnancy: an update
Elisabetta Torlone1, Graziano Di Cianni, Domenico Mannino
1Dipartimento Medicina Interna Endocrinologia e Metabolismo, Azienda Ospedaliera S. Maria della Misericordia, Perugia, Italy. elisabetta.torlone@ospedale.perugia.it
Acta Diabetologica
|July 3, 2009
Summary
Insulin analogs like aspart and lispro show promise for improving glycemic control in pregnant women with diabetes, with no observed adverse effects. Further research is needed for glulisine and detemir, while glargine use in pregnancy is not recommended.
Area of Science:
- Endocrinology
- Reproductive Medicine
- Pharmacology
Background:
- Good metabolic control in pregnancy is crucial for reducing maternal and fetal complications in diabetes.
- Optimizing insulin therapy before and during pregnancy is essential for managing diabetes effectively.
Purpose of the Study:
- To review the potential benefits and risks of using insulin analogs during pregnancy.
- To assess the safety and efficacy of specific insulin analogs in pregnant women with diabetes.
Main Methods:
- Review of clinical and experimental data on insulin aspart, lispro, glulisine, glargine, and detemir.
- Analysis of published studies, including retrospective and case-control studies, on insulin use in pregnancy.
Main Results:
- Insulin aspart and lispro show no adverse maternal or fetal effects, improving glycemic control and patient satisfaction.
- Limited data exists for glulisine; glargine is not recommended, though recent studies show similar malformation rates to human insulin in 335 pregnancies.
- No published data on detemir, with a prospective study expected in 2010.
Conclusions:
- Insulin aspart and lispro appear safe and effective for managing diabetes during pregnancy.
- Further research is required for glulisine and detemir, and caution is advised with glargine use in pregnancy.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...